 Inna Lobeck
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biliary Atresia | 8 | 2021 | 10 | 2.570 |
Why?
| | Rotavirus | 6 | 2021 | 18 | 1.190 |
Why?
| | Choledochal Cyst | 2 | 2017 | 3 | 1.140 |
Why?
| | Fetal Diseases | 2 | 2023 | 9 | 1.110 |
Why?
| | Airway Obstruction | 2 | 2023 | 20 | 1.110 |
Why?
| | Capsid Proteins | 4 | 2017 | 4 | 0.980 |
Why?
| | Fetofetal Transfusion | 1 | 2024 | 1 | 0.960 |
Why?
| | Microwaves | 1 | 2024 | 1 | 0.960 |
Why?
| | Ultrasonography, Prenatal | 1 | 2024 | 9 | 0.960 |
Why?
| | Rotavirus Infections | 4 | 2021 | 20 | 0.910 |
Why?
| | Fetal Therapies | 1 | 2023 | 2 | 0.900 |
Why?
| | Humans | 17 | 2024 | 6896 | 0.810 |
Why?
| | Female | 12 | 2024 | 3525 | 0.810 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2018 | 16 | 0.640 |
Why?
| | Male | 10 | 2023 | 3337 | 0.640 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 2 | 0.610 |
Why?
| | Hypertension, Renovascular | 1 | 2017 | 4 | 0.610 |
Why?
| | Endovascular Procedures | 1 | 2017 | 5 | 0.610 |
Why?
| | Bile Ducts, Extrahepatic | 2 | 2017 | 3 | 0.610 |
Why?
| | Antihypertensive Agents | 1 | 2017 | 13 | 0.610 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 3 | 0.580 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 3 | 0.580 |
Why?
| | Intestinal Neoplasms | 1 | 2017 | 3 | 0.580 |
Why?
| | Aftercare | 1 | 2017 | 5 | 0.580 |
Why?
| | Hodgkin Disease | 1 | 2016 | 3 | 0.570 |
Why?
| | Survivors | 1 | 2016 | 18 | 0.560 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 2 | 0.560 |
Why?
| | Extremities | 1 | 2016 | 3 | 0.560 |
Why?
| | Lymph Nodes | 1 | 2016 | 3 | 0.560 |
Why?
| | Lymph Node Excision | 1 | 2016 | 4 | 0.560 |
Why?
| | Antigens, Viral | 1 | 2016 | 8 | 0.560 |
Why?
| | Transition to Adult Care | 1 | 2016 | 19 | 0.560 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 7 | 0.560 |
Why?
| | Rhabdomyosarcoma | 1 | 2016 | 6 | 0.560 |
Why?
| | Infant | 6 | 2021 | 1446 | 0.550 |
Why?
| | Guideline Adherence | 1 | 2016 | 36 | 0.540 |
Why?
| | Colon | 1 | 2016 | 14 | 0.530 |
Why?
| | Tracheoesophageal Fistula | 1 | 2016 | 27 | 0.520 |
Why?
| | Esophageal Atresia | 1 | 2016 | 32 | 0.520 |
Why?
| | Retrospective Studies | 6 | 2017 | 1296 | 0.520 |
Why?
| | Appendectomy | 1 | 2017 | 100 | 0.510 |
Why?
| | Infant, Newborn | 5 | 2023 | 816 | 0.490 |
Why?
| | Pregnancy | 3 | 2024 | 216 | 0.480 |
Why?
| | Child | 7 | 2023 | 3364 | 0.470 |
Why?
| | Disease Models, Animal | 5 | 2021 | 71 | 0.430 |
Why?
| | Adult | 4 | 2024 | 1181 | 0.410 |
Why?
| | Adolescent | 4 | 2017 | 2197 | 0.360 |
Why?
| | Child, Preschool | 4 | 2021 | 1569 | 0.330 |
Why?
| | Treatment Outcome | 4 | 2021 | 622 | 0.310 |
Why?
| | Mice | 5 | 2021 | 348 | 0.300 |
Why?
| | Animals | 6 | 2021 | 729 | 0.280 |
Why?
| | Follow-Up Studies | 2 | 2017 | 304 | 0.260 |
Why?
| | Mice, Inbred BALB C | 4 | 2020 | 29 | 0.250 |
Why?
| | Postoperative Complications | 2 | 2016 | 184 | 0.240 |
Why?
| | Ablation Techniques | 1 | 2024 | 1 | 0.240 |
Why?
| | Pregnancy, Twin | 1 | 2024 | 1 | 0.240 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 5 | 0.240 |
Why?
| | Goiter | 1 | 2023 | 2 | 0.230 |
Why?
| | Cesarean Section | 1 | 2023 | 5 | 0.220 |
Why?
| | Uterus | 1 | 2023 | 10 | 0.220 |
Why?
| | North America | 1 | 2023 | 44 | 0.220 |
Why?
| | Specialties, Surgical | 1 | 2023 | 14 | 0.210 |
Why?
| | Internship and Residency | 1 | 2023 | 39 | 0.210 |
Why?
| | HMGB1 Protein | 1 | 2021 | 1 | 0.200 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 3 | 0.200 |
Why?
| | Reassortant Viruses | 1 | 2020 | 2 | 0.180 |
Why?
| | Liver Cirrhosis | 1 | 2020 | 10 | 0.180 |
Why?
| | Macaca mulatta | 2 | 2017 | 24 | 0.180 |
Why?
| | Constriction, Pathologic | 1 | 2017 | 19 | 0.150 |
Why?
| | Point Mutation | 1 | 2017 | 7 | 0.150 |
Why?
| | Mutant Proteins | 1 | 2017 | 6 | 0.150 |
Why?
| | Cholangitis | 1 | 2017 | 3 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 2 | 0.140 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 77 | 0.140 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 2016 | 1 | 0.140 |
Why?
| | Laparotomy | 1 | 2016 | 21 | 0.140 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 3 | 0.140 |
Why?
| | SEER Program | 1 | 2016 | 7 | 0.140 |
Why?
| | Biological Transport | 1 | 2016 | 19 | 0.140 |
Why?
| | Phosphorylation | 1 | 2016 | 22 | 0.140 |
Why?
| | Neoplasm Staging | 1 | 2016 | 33 | 0.140 |
Why?
| | Survival Analysis | 1 | 2016 | 50 | 0.140 |
Why?
| | Calcium | 1 | 2016 | 41 | 0.140 |
Why?
| | Ultrasonography | 1 | 2016 | 46 | 0.140 |
Why?
| | Incidence | 1 | 2016 | 133 | 0.140 |
Why?
| | Testis | 1 | 2016 | 26 | 0.140 |
Why?
| | Burns, Chemical | 1 | 2016 | 2 | 0.130 |
Why?
| | Esophageal Stenosis | 1 | 2016 | 7 | 0.130 |
Why?
| | Prognosis | 1 | 2016 | 211 | 0.130 |
Why?
| | Time Factors | 1 | 2016 | 250 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 108 | 0.130 |
Why?
| | Esophagus | 1 | 2016 | 29 | 0.130 |
Why?
| | Pharyngitis | 1 | 2016 | 16 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2015 | 1 | 0.130 |
Why?
| | Cholestasis | 1 | 2015 | 2 | 0.130 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 16 | 0.130 |
Why?
| | Animals, Newborn | 3 | 2021 | 32 | 0.120 |
Why?
| | Bile Ducts | 3 | 2021 | 5 | 0.120 |
Why?
| | United States | 1 | 2016 | 669 | 0.110 |
Why?
| | Virus Replication | 3 | 2017 | 9 | 0.110 |
Why?
| | Cell Line | 2 | 2021 | 81 | 0.090 |
Why?
| | Piracetam | 1 | 2009 | 1 | 0.090 |
Why?
| | Phenytoin | 1 | 2009 | 9 | 0.090 |
Why?
| | Hypotension | 1 | 2009 | 5 | 0.090 |
Why?
| | Seizures | 1 | 2009 | 25 | 0.090 |
Why?
| | Blood Pressure | 1 | 2009 | 67 | 0.080 |
Why?
| | Airway Management | 1 | 2023 | 3 | 0.060 |
Why?
| | Health Care Costs | 1 | 2023 | 33 | 0.060 |
Why?
| | Inpatients | 1 | 2023 | 44 | 0.060 |
Why?
| | Employment | 1 | 2023 | 5 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 17 | 0.050 |
Why?
| | Hospitals | 1 | 2023 | 36 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2021 | 1 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2021 | 7 | 0.050 |
Why?
| | Bilirubin | 1 | 2021 | 26 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 274 | 0.050 |
Why?
| | Biomarkers | 1 | 2021 | 136 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 137 | 0.050 |
Why?
| | Jaundice, Obstructive | 1 | 2020 | 1 | 0.040 |
Why?
| | Risk Factors | 1 | 2021 | 487 | 0.040 |
Why?
| | Reverse Genetics | 1 | 2017 | 1 | 0.040 |
Why?
| | Viral Tropism | 1 | 2017 | 2 | 0.040 |
Why?
| | Virus Attachment | 1 | 2017 | 1 | 0.040 |
Why?
| | Random Allocation | 1 | 2017 | 7 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2017 | 18 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2017 | 84 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 51 | 0.030 |
Why?
| | Viral Plaque Assay | 1 | 2015 | 2 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2015 | 5 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2015 | 13 | 0.030 |
Why?
| | Phylogeny | 1 | 2015 | 24 | 0.030 |
Why?
| | Liver | 1 | 2015 | 126 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 33 | 0.020 |
Why?
| | Medical Records | 1 | 2009 | 14 | 0.020 |
Why?
| | Regression Analysis | 1 | 2009 | 52 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2009 | 151 | 0.020 |
Why?
| | Patient Selection | 1 | 2009 | 40 | 0.020 |
Why?
| | Aged | 1 | 2009 | 378 | 0.020 |
Why?
| | Middle Aged | 1 | 2009 | 608 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|